Comparative Pharmacology
Head-to-head clinical analysis: CLINIMIX E 2 75 5 SULFITE FREE W ELECT IN DEXTROSE 5 W CALCIUM IN PLASTIC CONTAINER versus CLINISOL 15 SULFITE FREE IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLINIMIX E 2 75 5 SULFITE FREE W ELECT IN DEXTROSE 5 W CALCIUM IN PLASTIC CONTAINER versus CLINISOL 15 SULFITE FREE IN PLASTIC CONTAINER.
CLINIMIX E 2.75/5 SULFITE FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER vs CLINISOL 15% SULFITE FREE IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
CLINIMIX E 2.75/5 is a combination of amino acids, electrolytes, and dextrose used for parenteral nutrition. The amino acids provide substrates for protein synthesis, dextrose supplies caloric energy, and electrolytes maintain acid-base and fluid balance. Calcium is included for bone health and neuromuscular function.
Provides essential amino acids and calories for protein synthesis and energy metabolism in parenteral nutrition.
Intravenous administration. The dose is individualized based on patient's metabolic requirements, clinical condition, and tolerance. Typical adult dose: 1 to 2 L per day of CLINIMIX E 2.75/5 with electrolytes in 5% dextrose with calcium, infused at a rate not exceeding 4 mg/kg/min of dextrose (or as tolerated).
Intravenous infusion: 1.5 g/kg/day (amino acids) as part of parenteral nutrition; typical infusion rate 0.8-1.5 g/kg/hr.
None Documented
None Documented
Not applicable as a single entity; components have independent half-lives. Amino acids have plasma half-lives of minutes to hours depending on individual amino acid and metabolic state. Dextrose has an elimination half-life of 1.5-2.5 hours in normal glucose tolerance. Electrolytes are not described by half-life due to homeostatic regulation.
Amino acids have variable individual half-lives; the terminal elimination half-life for the amino acid mixture is approximately 1.5–2 hours, reflecting rapid distribution and metabolism; clinically, cessation of infusion leads to rapid decline in plasma amino acid levels.
CLINIMIX E 2.75/5 is a parenteral nutrition solution; components are eliminated via normal metabolic pathways. Amino acids undergo deamination and oxidation, with nitrogen excreted renally as urea (80-90%). Glucose is metabolized to CO2 and water, excreted via lungs and kidneys. Electrolytes are excreted renally in proportion to intake and homeostatic regulation.
Renal (primarily as amino acids and metabolites); >90% of infused amino acids are eliminated via renal excretion as nitrogenous waste (urea, ammonia) and oxidized to CO2 and water; <10% excreted unchanged in bile/feces.
Category C
Category C
Parenteral Nutrition Solution
Parenteral Nutrition Solution